Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 413K) PPT slides of all figures Correction (v196,p557) Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Li, Y. Articles by Hicklin, D. J. Search for Related Content PubMed PubMed Citation Articles by Li, Y. Articles by Hicklin, D. J. Social Bookmarking                      What's this?

Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis

Yiwen Li, Mei-Nai Wang, Hongli Li, Karen D. King, Rajiv Bassi, Haijun Sun, Angel Santiago, Andrea T. Hooper, Peter Bohlen and Daniel J. Hicklin

ImClone Systems Incorporated, New York, NY 10014

Address correspondence to Dr. Yiwen Li, Department of Immunology, ImClone Systems Incorporated, 180 Varick St., New York, NY 10014. Phone: 212-638-5173; Fax: 212-645-2054; E-mail: yiwen{at}imclone.com

The vascular endothelial growth factor (VEGF) receptor fetal liver kinase 1 (flk1; VEGFR-2, KDR) is an endothelial cell–specific receptor tyrosine kinase that mediates physiological and pathological angiogenesis. We hypothesized that an active immunotherapy approach targeting flk1 may inhibit tumor angiogenesis and metastasis. To test this hypothesis, we first evaluated whether immune responses to flk1 could be elicited in mice by immunization with dendritic cells pulsed with a soluble flk1 protein (DC-flk1). This immunization generated flk1-specific neutralizing antibody and CD8⁺ cytotoxic T cell responses, breaking tolerance to self-flk1 antigen. Tumor-induced angiogenesis was suppressed in immunized mice as measured in an alginate bead assay. Development of pulmonary metastases was strongly inhibited in DC-flk1–immunized mice challenged with B16 melanoma or Lewis lung carcinoma cells. DC-flk1 immunization also significantly prolonged the survival of mice challenged with Lewis lung tumors. Thus, an active immunization strategy that targets an angiogenesis-related antigen on endothelium can inhibit angiogenesis and may be a useful approach for treating angiogenesis-related diseases.

Key Words: angiogenesis • antibody • cytotoxic T lymphocytes • cancer vaccine • tumor antigen

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Seavey, M. M., Maciag, P. C., Al-Rawi, N., Sewell, D., Paterson, Y. (2009). An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model. J. Immunol. 182: 5537-5546 [Abstract] [Full Text]  
• Sun, Y., Song, M., Jager, E., Schwer, C., Stevanovic, S., Flindt, S., Karbach, J., Nguyen, X. D., Schadendorf, D., Cichutek, K. (2008). Human CD4+ T Lymphocytes Recognize a Vascular Endothelial Growth Factor Receptor-2-Derived Epitope in Association with HLA-DR. Clin. Cancer Res. 14: 4306-4315 [Abstract] [Full Text]  
• Mochimaru, H., Usui, T., Yaguchi, T., Nagahama, Y., Hasegawa, G., Usui, Y., Shimmura, S., Tsubota, K., Amano, S., Kawakami, Y., Ishida, S. (2008). Suppression of Alkali Burn-Induced Corneal Neovascularization by Dendritic Cell Vaccination Targeting VEGF Receptor 2. IOVS 49: 2172-2177 [Abstract] [Full Text]  
• Wang, Y.-s., Wang, G.-q., Wen, Y.-j., Wang, L., Chen, X.-c., Chen, P., Kan, B., Li, J., Huang, C., Lu, Y., Zhou, Q., Xu, N., Li, D., Fan, L.-y., Yi, T., Wu, H.-b., Wei, Y.-q. (2007). Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine {beta}-Defensin 2 and mFlk-1. Clin. Cancer Res. 13: 6779-6787 [Abstract] [Full Text]  
• Mochimaru, H., Nagai, N., Hasegawa, G., Kudo-Saito, C., Yaguchi, T., Usui, Y., Kurihara, T., Koto, T., Satofuka, S., Shinoda, H., Ozawa, Y., Tsubota, K., Kawakami, Y., Ishida, S. (2007). Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2. IOVS 48: 4795-4801 [Abstract] [Full Text]  
• Hauer, A. D., van Puijvelde, G. H.M., Peterse, N., de Vos, P., van Weel, V., van Wanrooij, E. J.A., Biessen, E. A.L., Quax, P. H.A., Niethammer, A. G., Reisfeld, R. A., van Berkel, T. J.C., Kuiper, J. (2007). Vaccination Against VEGFR2 Attenuates Initiation and Progression of Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 27: 2050-2057 [Abstract] [Full Text]  
• Ko, E., Luo, W., Peng, L., Wang, X., Ferrone, S. (2007). Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity. Cancer Res. 67: 7875-7884 [Abstract] [Full Text]  
• Varker, K. A., Biber, J. E., Kefauver, C., Jensen, R., Lehman, A., Young, D., Wu, H., Lesinski, G. B., Kendra, K., Chen, H. X., Walker, M. J., Carson, W. E. III (2007). A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma. Ann. Surg. Oncol. 14: 2367-2376 [Abstract] [Full Text]  
• Shi, M., Hao, S., Chan, T., Xiang, J. (2006). CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. J. Leukoc. Biol. 80: 1354-1363 [Abstract] [Full Text]  
• Ishizaki, H., Tsunoda, T., Wada, S., Yamauchi, M., Shibuya, M., Tahara, H. (2006). Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.. Clin. Cancer Res. 12: 5841-5849 [Abstract] [Full Text]  
• Kim, B., Suvas, S., Sarangi, P. P., Lee, S., Reisfeld, R. A., Rouse, B. T. (2006). Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects. J. Immunol. 177: 4122-4131 [Abstract] [Full Text]  
• Holmgren, L., Ambrosino, E., Birot, O., Tullus, C., Veitonmaki, N., Levchenko, T., Carlson, L.-M., Musiani, P., Iezzi, M., Curcio, C., Forni, G., Cavallo, F., Kiessling, R. (2006). A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc. Natl. Acad. Sci. USA 103: 9208-9213 [Abstract] [Full Text]  
• Sun, Y., Stevanovic, S., Song, M., Schwantes, A., Kirkpatrick, C. J., Schadendorf, D., Cichutek, K. (2006). The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Blood 107: 1476-1483 [Abstract] [Full Text]  
• Lee, J., Fassnacht, M., Nair, S., Boczkowski, D., Gilboa, E. (2005). Tumor Immunotherapy Targeting Fibroblast Activation Protein, a Product Expressed in Tumor-Associated Fibroblasts. Cancer Res. 65: 11156-11163 [Abstract] [Full Text]  
• Fassnacht, M., Lee, J., Milazzo, C., Boczkowski, D., Su, Z., Nair, S., Gilboa, E. (2005). Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy. Clin. Cancer Res. 11: 5566-5571 [Abstract] [Full Text]  
• Xiang, J., Huang, H., Liu, Y. (2005). A New Dynamic Model of CD8+ T Effector Cell Responses via CD4+ T Helper-Antigen-Presenting Cells. J. Immunol. 174: 7497-7505 [Abstract] [Full Text]  
• Wada, S., Tsunoda, T., Baba, T., Primus, F. J., Kuwano, H., Shibuya, M., Tahara, H. (2005). Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2. Cancer Res. 65: 4939-4946 [Abstract] [Full Text]  
• Li, Y., Li, H., Wang, M.-N., Lu, D., Bassi, R., Wu, Y., Zhang, H., Balderes, P., Ludwig, D. L., Pytowski, B., Kussie, P., Piloto, O., Small, D., Bohlen, P., Witte, L., Zhu, Z., Hicklin, D. J. (2004). Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood 104: 1137-1144 [Abstract] [Full Text]  
• Bjorndahl, M., Cao, R., Eriksson, A., Cao, Y. (2004). Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion. Circ. Res. 94: 1443-1450 [Abstract] [Full Text]  
• Mendoza, L., Valcarcel, M., Carrascal, T., Egilegor, E., Salado, C., Sim, B. K. L., Vidal-Vanaclocha, F. (2004). Inhibition of Cytokine-Induced Microvascular Arrest of Tumor Cells by Recombinant Endostatin Prevents Experimental Hepatic Melanoma Metastasis. Cancer Res. 64: 304-310 [Abstract] [Full Text]  
• Nair, S., Boczkowski, D., Moeller, B., Dewhirst, M., Vieweg, J., Gilboa, E. (2003). Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102: 964-971 [Abstract] [Full Text]  
• Posey, J. A., Ng, T. C., Yang, B., Khazaeli, M. B., Carpenter, M. D., Fox, F., Needle, M., Waksal, H., LoBuglio, A. F. (2003). A Phase I Study of Anti-Kinase Insert Domain-containing Receptor Antibody, IMC-1C11, in Patients with Liver Metastases from Colorectal Carcinoma. Clin. Cancer Res. 9: 1323-1332 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS